12:00 AM
 | 
Mar 04, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

ToleroMune cat allergy therapy: Additional Phase II data

Data from 50 evaluable patients with confirmed cat allergies in a 2-year follow-up of a double-blind, Canadian Phase II trial showed that patients previously treated with 4 doses of ToleroMune over 12 weeks had a significant improvement in total rhinoconjunctivitis symptom score following a cat allergen challenge 2 years later without additional treatment vs. placebo (50%...

Read the full 260 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >